Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2012-07-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-012-2171-9PMID 22825030
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

  2012cited by this paper
• Aurora kinase inhibitors: Progress towards the clinic

  2012cited by this paper
• Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2011cited by this paper
• Triple negative breast cancer: unmet medical needs

  2011cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells

  2010cited by this paper
• Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

  2010influential reference
• Phase I-II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium trial P7703.

  2009cited by this paper
• Vorinostat in solid and hematologic malignancies

  2009cited by this paper
• Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

  2009cited by this paper
• Histone deacetylase inhibitors induce mitotic slippage

  2008cited by this paper
• Aurora kinases as targets for cancer therapy.

  2008cited by this paper
• Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.

  2008influential reference
• Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells

  2008cited by this paper
• Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

  2008cited by this paper
• Regulation of mitosis via mitotic kinases: new opportunities for cancer management.

  2008cited by this paper
• Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.

  2008cited by this paper
• VX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells

  2007influential reference
• Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase

  2007cited by this paper
• Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

  2007cited by this paper
• AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

  2007cited by this paper
• Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90

  2007cited by this paper
• High copy amplification of the aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers

  2007cited by this paper
• Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia.

  2007cited by this paper
• Roles of Aurora Kinases in Mitosis and Tumorigenesis

  2007cited by this paper
• Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation

  2006cited by this paper
• Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

  2006cited by this paper
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006cited by this paper
• A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity.

  2006cited by this paper
• The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.

  2006influential reference
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005cited by this paper
• Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

  2005influential reference
• Aurora-A — A guardian of poles

  2005cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004cited by this paper
• Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.

  2003cited by this paper
• Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

  2002cited by this paper
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

  2000cited by this paper
• Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

  1998cited by this paper
• Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma

  1997cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• The Potential Biological Roles and Clinical Significance of Anaphase-Promoting Complex Subunit 1 in Colorectal Cancer

  2025cites this paper
• Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer

  2023cites this paper
• Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

  2023cites this paper
• Recent Updates on Oncogenic Signaling of Aurora Kinases in Chemosensitive, Chemoresistant Cancers: Novel Medicinal Chemistry Approaches for Targeting Aurora Kinases.

  2023cites this paper
• Vorinostat (SAHA) and Breast Cancer: An Overview

  2021cites this paper
• Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

  2021cites this paper
• Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells

  2019cites this paper
• Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors

  2018cites this paper
• Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models

  2018cites this paper
• An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression

  2018cites this paper
• Breast cancer intrinsic subtypes: a critical conception in bioinformatics

  2017cites this paper
• Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy

  2016cites this paper
• Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer

  2016cites this paper
• In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor.

  2016cites this paper
• Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family

  2015cites this paper
• Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy

  2015cites this paper
• The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set

  2015cites this paper
• Effect of survivin siRNA on biological behaviour of breast cancer MCF7 cells.

  2015cites this paper
• Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer

  2014cites this paper
• Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers

  2014cites this paper
• Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.

  2014cites this paper
• Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells

  2014cites this paper
• Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

  2014cites this paper
• Regulation of Histone Acyltransferases and Deacetylases by Bioactive Food Compounds for the Prevention of Chronic Diseases

  2014cites this paper
• Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat.

  2013cites this paper
• BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database

  2013cites this paper
• Mitosis-targeting therapies: a troubleshooting guide.

  2013cites this paper
• Emerging targeted agents in metastatic breast cancer

  2013cites this paper
• Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer

  2013cites this paper
• Modification of RHAMM and TPX2 optimizes Aurora kinase A (AURKA) inhibition in malignant peripheral nerve sheath tumours

  2013cites this paper
• Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor,

  2013cites this paper